Amylyx reports a 55% reduction in hypoglycemic events with avexitide in the Phase 3 LUCIDITY trial, advancing treatment development for post-bariatric hypoglycemia.
Written By: Pavani Polepaka, PharmD
Reviewed By: Pharmacally Editorial Team
Amylyx Pharmaceuticals reported positive Phase 3 results for avexitide in adults with post-bariatric hypoglycemia (PBH), meeting the primary endpoint of the LUCIDITY trial with a 55% reduction in Level 2 and Level 3 hypoglycemic events compared with placebo. The findings support the potential of the investigational GLP-1 receptor antagonist as a first approved pharmacological treatment for a condition with no currently FDA-approved therapy.
Phase 3 Trial Meets Primary Endpoint with High Statistical Significance
The 16-week double-blind treatment period of LUCIDITY demonstrated a significant reduction in the composite rate of self-monitoring of blood glucose (SMBG)-confirmed Level 2 and Event Adjudication Committee (EAC)-adjudicated Level 3 hypoglycemic events.
The least-squares mean event rate was 0.55 events per week with avexitide, compared with 1.24 events per week with placebo, representing a 55% reduction (p=0.0000034).
Avexitide also met all prespecified, multiplicity-controlled secondary event-rate endpoints:
- SMBG-confirmed Level 2 hypoglycemic events: 63% reduction (p=0.0000032).
- EAC-adjudicated Level 3 hypoglycemic events: 47% reduction (p=0.0016).
- Continuous glucose monitoring (CGM)-detected Level 2 events: 42% reduction (p=0.00016).
A secondary analysis of changes from baseline showed that hypoglycemic events decreased by 72.9% in the avexitide group and 37.8% in the placebo group, with a statistically significant between-group difference (p=0.000034).
Avexitide Targets GLP-1-Driven Insulin Secretion
Post-bariatric hypoglycemia is a chronic metabolic complication that can develop following bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB). An exaggerated glucagon-like peptide-1 (GLP-1) response after food intake can stimulate excessive insulin secretion, causing recurrent and sometimes severe reductions in blood glucose.
Severe episodes can produce neuroglycopenia, resulting in confusion, cognitive dysfunction, loss of consciousness and seizures. The condition can also compromise independent living and quality of life.
Avexitide is an investigational, first-in-class competitive GLP-1 receptor antagonist. It blocks GLP-1 receptor signalling on pancreatic islet beta cells, reducing excessive insulin secretion associated with PBH and helping stabilize blood glucose levels.
The condition is estimated to affect approximately 8% of people in the United States who undergo sleeve gastrectomy or RYGB, representing around 160,000 individuals. Dietary management remains a central component of care, but no pharmacological treatment has received FDA approval specifically for PBH.
LUCIDITY Enrolled 78 Adults Across 21 US Sites
The randomized, double-blind, placebo-controlled Phase 3 trial (NCT06747468) enrolled 78 adults with PBH following RYGB surgery across 21 US sites.
Following a three-week run-in period, participants were randomized in a 3:2 ratio to receive either avexitide 90 mg subcutaneously once daily or placebo for 16 weeks. Both groups continued standard-of-care dietary management.
More than 90% of participants completed the double-blind treatment period, including 45 of 47 participants receiving avexitide and 28 of 31 receiving placebo.
The study population had substantial disease burden at baseline. Daily hypoglycemic symptoms were reported by 68% of participants, while 47% had a history of loss of consciousness and 28% had experienced hypoglycemia-related hospitalizations.
Safety Profile Remains Consistent with Earlier Trials
Avexitide was generally well tolerated, with treatment-emergent adverse events primarily involving gastrointestinal symptoms and injection-site reactions. Most events were mild to moderate in severity.
No deaths or treatment-related serious adverse events occurred during the double-blind treatment period. Investigators also reported no clinically meaningful changes in body weight or fasting plasma glucose.
The safety findings were consistent with those observed in previous PBH clinical studies, although longer-term follow-up remains important.
Amylyx Targets NDA Submission by Year-End 2026
Amylyx plans to submit a New Drug Application (NDA) to the US Food and Drug Administration by the end of 2026 and is preparing for a potential commercial launch in 2027, subject to regulatory approval.
The FDA has previously granted avexitide Breakthrough Therapy Designation for PBH. The trial’s 32-week open-label extension and an expanded access programme for eligible adults following RYGB surgery remain ongoing.
The Phase 3 findings build on positive results from earlier avexitide studies and establish a stronger clinical evidence base for targeting GLP-1-mediated insulin secretion in PBH. However, regulatory review and longer-term safety and efficacy data will determine whether these results translate into the first approved pharmacological treatment for the condition.
Reference
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting, Amylyx, 14 November 2026
Avexitide for Treatment of Post-Bariatric Hypoglycemia (LUCIDITY), ClinicalTrials.gov ID NCT06747468
About the Writer
Pavani Polepaka, Pharm.D., (Linkedin) is a clinically trained pharmacy professional with hands-on exposure to hospital settings and experience in patient case documentation, medical record review, adverse drug reaction (ADR) reporting, pharmacovigilance, literature review and patient counselling. She possesses a strong foundation in pharmacotherapy, drug safety, clinical research and evidence-based healthcare practices, with an interest in translating clinical evidence into scientifically accurate medical content. She demonstrates research and analytical skills through academic activities and medical literature evaluation.
